IDEXX Laboratories Quarterly Balance Sheet
NASDAQ: IDXXHealth CareBiotechnology: In Vitro & In Vivo Diagnostic SubstancesUSD
At close: Oct 9, 4:00 PM ET · Delayed 15 min
IDEXX Laboratories financial position
As of Jun 30, 2026, IDEXX Laboratories reported total assets of $3.44 billion, up 3.3% from a year earlier against total liabilities of $1.83 billion. Shareholders' equity stood at $1.61 billion, or 46.8% of assets. The company held $196.9 million in cash and equivalents against $449.9 million of debt, a net debt position of $252.9 million.
The current ratio (current assets divided by current liabilities) was 1.17, meaning short-term assets cover obligations due within a year. Debt-to-equity was 0.28.
Summary generated from market data by MetaCap's automated system. Methodology
IDEXX Laboratories balance sheet (quarterly)
| Quarter (USD) | Q2 20262026-06-30 | Q1 20262026-03-31 | Q4 20252025-12-31 | Q3 20252025-09-30 | Q2 20252025-06-30 | Q1 20252025-03-31 | Q4 20242024-12-31 | Q3 20242024-09-30 | Q2 20242024-06-30 | Q1 20242024-03-31 | Q4 20232023-12-31 | Q3 20232023-09-30 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | 196.93M | 200.53M | 180.07M | 208.17M | 164.59M | 163.97M | 288.27M | 308.64M | 401.59M | 397.43M | 453.93M | 331.70M |
| Receivables | 627.08M | 603.54M | 552.38M | 566.88M | 560.56M | 527.46M | 473.57M | 511.25M | 533.61M | 507.21M | 457.44M | 452.70M |
| Inventory | 391.58M | 382.40M | 377.76M | 391.56M | 392.58M | 395.99M | 381.88M | 389.80M | 379.96M | 390.60M | 380.28M | 393.97M |
| Total Current Assets | 1.51B | 1.45B | 1.41B | 1.48B | 1.36B | 1.32B | 1.40B | 1.43B | 1.53B | 1.50B | 1.50B | 1.38B |
| Property, Plant & Equipment | 733.24M | 740.38M | 747.38M | 739.44M | 739.68M | 717.62M | 713.12M | 717.75M | 708.18M | 708.73M | 702.18M | 687.10M |
| Goodwill | 410.95M | 412.10M | 414.00M | 413.65M | 414.49M | 407.49M | 405.10M | 412.07M | 408.02M | 408.67M | 366.00M | 361.77M |
| Intangible Assets | 98.17M | 104.75M | 109.84M | 114.79M | 103.73M | 107.41M | 111.68M | 106.89M | 110.81M | 115.35M | 84.50M | 87.13M |
| Total Assets | 3.44B | 3.39B | 3.35B | 3.39B | 3.33B | 3.21B | 3.29B | 3.35B | 3.41B | 3.35B | 3.26B | 3.09B |
| Accounts Payable | 129.10M | 129.97M | 110.41M | 122.27M | 116.58M | 120.10M | 114.21M | 110.60M | 117.47M | 117.46M | 110.64M | 112.61M |
| Short-Term Debt | 150.00M | 150.00M | 75.00M | 150.00M | 74.99M | 170.93M | 167.79M | 99.14M | 170.11M | 75.00M | 75.00M | 149.99M |
| Total Current Liabilities | 1.29B | 1.30B | 1.15B | 1.25B | 1.22B | 1.14B | 1.07B | 1.01B | 1.12B | 956.90M | 951.55M | 970.19M |
| Long-Term Debt | 299.87M | 299.85M | 374.84M | 374.82M | 449.81M | 449.80M | 449.79M | 524.76M | 524.74M | 620.78M | 622.88M | 618.81M |
| Total Liabilities | 1.83B | 1.83B | 1.75B | 1.83B | 1.87B | 1.77B | 1.70B | 1.73B | 1.83B | 1.78B | 1.78B | 1.79B |
| Shareholders' Equity | 1.61B | 1.56B | 1.61B | 1.56B | 1.46B | 1.45B | 1.60B | 1.62B | 1.58B | 1.57B | 1.48B | 1.30B |
| Retained Earnings | 7.01B | 6.67B | 6.39B | 6.14B | 5.87B | 5.58B | 5.33B | 5.12B | 4.88B | 4.68B | 4.44B | 4.25B |
| Total Debt | 449.86M | 449.85M | 449.84M | 524.82M | 524.81M | 620.73M | 617.57M | 623.90M | 694.86M | 695.78M | 697.88M | 768.80M |
| Net Cash (Debt) | -252.93M | -249.32M | -269.77M | -316.66M | -360.21M | -456.76M | -329.31M | -315.26M | -293.26M | -298.34M | -243.95M | -437.11M |
| Shares Outstanding | 78.87M | 79.24M | 79.71M | 80.00M | 80.15M | 80.74M | 81.60M | 82.04M | 82.48M | 82.87M | 83.03M | 83.07M |
This table shows 12 quarterly periods of IDEXX Laboratories's balance sheet, from Q2 2026 back to Q3 2023, across 19 line items including cash & equivalents, short-term investments, receivables. Values in USD; B = billions, M = millions. Fiscal periods follow IDXX's reporting calendar. What is a balance sheet?